- Home
- DBRG vs RGC Comparison
DBRG vs RGC Comparison
Compare DBRG & RGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DBRG | RGC |
|---|---|---|
| Founded | 1991 | 2014 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.1B |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DBRG | RGC |
|---|---|---|
| Price | $15.88 | $5.88 |
| Analyst Decision | Hold | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $16.00 | N/A |
| AVG Volume (30 Days) | ★ 4.4M | 163.2K |
| Earning Date | 05-12-2026 | 10-31-2025 |
| Dividend Yield | ★ 0.26% | N/A |
| EPS Growth | ★ 557.14 | N/A |
| EPS | ★ 1.18 | N/A |
| Revenue | ★ $93,959,000.00 | N/A |
| Revenue This Year | $373.39 | N/A |
| Revenue Next Year | $8.23 | N/A |
| P/E Ratio | $13.48 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.94 | $4.51 |
| 52 Week High | $15.98 | $69.00 |
Technical Indicators
Market Signals| Indicator | DBRG | RGC |
|---|---|---|
| Relative Strength Index (RSI) | 45.19 | 49.33 |
| Support Level | $15.33 | $4.71 |
| Resistance Level | $15.92 | $6.40 |
| Average True Range (ATR) | 0.04 | 0.57 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 30.77 | 29.96 |
Price Performance
Historical ComparisonAbout DBRG DigitalBridge Group Inc.
DigitalBridge Group Inc is a developer of alternative asset manager dedicated to investing in digital infrastructure. The company's platform invests in and operates businesses across the digital ecosystem, including cell towers, data centres, fiber, small cells, and edge infrastructure, to provide clients with funds for digital infrastructure real estate infrastructure.
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.